Alvotech (NASDAQ: ALVO), a global biotech company specializing in
the development and manufacture of biosimilar medicines for
patients worldwide, today announced that its commercialization
partner in Japan, Fuji Pharma Co., Ltd. (“Fuji”), has received
marketing approval for AVT04 (ustekinumab), a biosimilar to
Stelara®, from the Japanese Ministry of Health, Labor and Welfare.
Based on publicly available information, AVT04 is the first
biosimilar to Stelara to be approved for sale in global markets.
Global sales of Stelara reached over $10 billion for the twelve
months preceding June 30, 2023, according to the manufacturer’s
public filings, making it one of the world’s highest grossing
biologics.
“We are thrilled to receive marketing approval for AVT04 in
Japan, which will be Alvotech’s second marketed biosimilar,” said
Robert Wessman, chairman and CEO of Alvotech. “Alvotech and Fuji
have a joint commitment to increase patient access to vital
biologic medicines, and based on our strong partnership, we believe
we will be able to serve the growing need for biosimilars in
Japan.”
AVT04 was developed using an Sp2/0 host cell line and is
manufactured by Alvotech using a continuous perfusion process. The
Sp2/0 host cell line allows for more efficient sialylation of the
molecule as compared to Chinese hamster ovary (CHO) cells and is
the same type of host cell line used to produce Stelara.
This is the first biosimilar approved under the commercial
partnership between Alvotech and Fuji, which also includes six
other biosimilar candidates to be developed and manufactured by
Alvotech and commercialized by Fuji in Japan. The partnership
agreement with Fuji was first announced in November 2018.
About AVT04 (ustekinumab) AVT04 is a monoclonal
antibody and a biosimilar candidate to Stelara® (ustekinumab).
Ustekinumab binds to two cytokines, IL-12 and IL-23, that are
involved in inflammatory and immune responses [1]. AVT04 is an
investigational product and has only been approved in Japan.
Dossiers are currently under evaluation in other major markets
globally.
About AlvotechAlvotech is a biotech company,
founded by Robert Wessman, focused solely on the development and
manufacture of biosimilar medicines for patients worldwide.
Alvotech seeks to be a global leader in the biosimilar space by
delivering high quality, cost-effective products, and services,
enabled by a fully integrated approach and broad in-house
capabilities. Alvotech’s current pipeline includes eight disclosed
biosimilar candidates aimed at treating autoimmune disorders, eye
disorders, osteoporosis, respiratory disease, and cancer. Alvotech
has formed a network of strategic commercial partnerships to
provide global reach and leverage local expertise in markets that
include the United States, Europe, Japan, China, and other Asian
countries and large parts of South America, Africa and the Middle
East. Alvotech’s commercial partners include Teva Pharmaceuticals,
a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA
Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma
(EEA, UK, Switzerland, Canada, Australia and New Zealand),
Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South
Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River
Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong,
Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and
Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi
Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs,
Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co.,
Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each
commercial partnership covers a unique set of product(s) and
territories. Except as specifically set forth therein, Alvotech
disclaims responsibility for the content of periodic filings,
disclosures and other reports made available by its partners. For
more information, please visit www.alvotech.com. None of the
information on the Alvotech website shall be deemed part of this
press release.
Forward Looking StatementsCertain statements in
this communication may be considered “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Forward-looking statements generally relate to
future events or the future financial operating performance of
Alvotech and may include, for example, Alvotech’s expectations
regarding its expected future business, financial performance, the
use of proceeds from the private placement, and the future
utilization of the Yorkville facility. In some cases, you can
identify forward-looking statements by terminology such as “may”,
“should”, “expect”, “intend”, “will”, “estimate”, “anticipate”,
“believe”, “predict”, “potential”, “aim” or “continue”, or the
negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks,
uncertainties, and other factors which could cause actual results
to differ materially from those expressed or implied by such
forward-looking statements. These forward-looking statements are
based upon estimates and assumptions that, while considered
reasonable by Alvotech and its management, are inherently uncertain
and are inherently subject to risks, variability, and
contingencies, many of which are beyond Alvotech’s control. Factors
that may cause actual results to differ materially from current
expectations include, but are not limited to: (1) the outcome of
any legal proceedings that may be instituted against Alvotech or
others following the business combination between Alvotech Holdings
S.A., Oaktree Acquisition Corp. II and Alvotech; (2) changes in
applicable laws or regulations; (3) the possibility that Alvotech
may be adversely affected by other economic, business, and/or
competitive factors; (4) Alvotech’s estimates of expenses and
profitability; (5) Alvotech’s ability to develop, manufacture and
commercialize the products and product candidates in its pipeline;
(6) actions of regulatory authorities, which may affect the
initiation, timing and progress of clinical studies or future
regulatory approvals or marketing authorizations; (7) the ability
of Alvotech or its partners to gain approval from regulators for
planned clinical studies, study plans or sites; (8) the ability of
Alvotech’s partners to conduct, supervise and monitor existing and
potential future clinical studies, which may impact development
timelines and plans; (9) Alvotech’s ability to obtain and maintain
regulatory approval or authorizations of its products, including
the timing or likelihood of expansion into additional markets or
geographies; (10) the success of Alvotech’s current and future
collaborations, joint ventures, partnerships or licensing
arrangements; (11) Alvotech’s ability, and that of its commercial
partners, to execute their commercialization strategy for approved
products; (12) Alvotech’s ability to manufacture sufficient
commercial supply of its approved products; (13) the outcome of
ongoing and future litigation regarding Alvotech’s products and
product candidates; (14) the potential impact of the ongoing
COVID-19 pandemic on the FDA’s review timelines, including its
ability to complete timely inspection of manufacturing sites; (15)
the impact of worsening macroeconomic conditions, including rising
inflation and interest rates and general market conditions, war in
Ukraine and global geopolitical tension, and the ongoing and
evolving COVID-19 pandemic on the Alvotech’s business, financial
position, strategy and anticipated milestones; (16) future
liquidity and financing needs, which may impact the anticipated
utilization of the Yorkville facility or other financing sources;
and (17) other risks and uncertainties set forth in the sections
entitled “Risk Factors” and “Cautionary Note Regarding
Forward-Looking Statements” in documents that Alvotech may from
time to time file or furnish with the SEC. There may be additional
risks that Alvotech does not presently know or that Alvotech
currently believes are immaterial that could also cause actual
results to differ from those contained in the forward-looking
statements. Nothing in this communication should be regarded as a
representation by any person that the forward-looking statements
set forth herein will be achieved or that any of the contemplated
results of such forward-looking statements will be achieved. You
should not place undue reliance on forward-looking statements,
which speak only as of the date they are made. Alvotech does not
undertake any duty to update these forward-looking statements or to
inform the recipient of any matters of which any of them becomes
aware of which may affect any matter referred to in this
communication. Alvotech disclaims any and all liability for any
loss or damage (whether foreseeable or not) suffered or incurred by
any person or entity as a result of anything contained or omitted
from this communication and such liability is expressly disclaimed.
The recipient agrees that it shall not seek to sue or otherwise
hold Alvotech or any of its directors, officers, employees,
affiliates, agents, advisors, or representatives liable in any
respect for the provision of this communication, the information
contained in this communication, or the omission of any information
from this communication.
[1]
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf
CONTACTSAlvotech Investor
RelationsBenedikt Stefanssonalvotech.ir@alvotech.com
Alvontech (NASDAQ:ALVO)
過去 株価チャート
から 11 2024 まで 12 2024
Alvontech (NASDAQ:ALVO)
過去 株価チャート
から 12 2023 まで 12 2024